Skip to main content
  • AACR Journals
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Radiation Oncology
      • Novel Combinations
      • Reviews
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Journals
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Cancer Therapeutics
Molecular Cancer Therapeutics
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Radiation Oncology
      • Novel Combinations
      • Reviews
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Cancer Biology and Signal Transduction

Stereospecific PARP Trapping by BMN 673 and Comparison with Olaparib and Rucaparib

Junko Murai, Shar-Yin N. Huang, Amèlie Renaud, Yiping Zhang, Jiuping Ji, Shunichi Takeda, Joel Morris, Beverly Teicher, James H. Doroshow and Yves Pommier
Junko Murai
1Developmental Therapeutics Branch, Laboratory of Molecular Pharmacology, Center for Cancer Research; 2National Clinical Target Validation Laboratory; 3Division of Cancer Treatment and Diagnosis, National Cancer Institute, NIH, Bethesda, Maryland; and 4Department of Radiation Genetics, Graduate School of Medicine, Kyoto University, Yoshidakonoe, Sakyo-ku, Kyoto, Japan
1Developmental Therapeutics Branch, Laboratory of Molecular Pharmacology, Center for Cancer Research; 2National Clinical Target Validation Laboratory; 3Division of Cancer Treatment and Diagnosis, National Cancer Institute, NIH, Bethesda, Maryland; and 4Department of Radiation Genetics, Graduate School of Medicine, Kyoto University, Yoshidakonoe, Sakyo-ku, Kyoto, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Shar-Yin N. Huang
1Developmental Therapeutics Branch, Laboratory of Molecular Pharmacology, Center for Cancer Research; 2National Clinical Target Validation Laboratory; 3Division of Cancer Treatment and Diagnosis, National Cancer Institute, NIH, Bethesda, Maryland; and 4Department of Radiation Genetics, Graduate School of Medicine, Kyoto University, Yoshidakonoe, Sakyo-ku, Kyoto, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Amèlie Renaud
1Developmental Therapeutics Branch, Laboratory of Molecular Pharmacology, Center for Cancer Research; 2National Clinical Target Validation Laboratory; 3Division of Cancer Treatment and Diagnosis, National Cancer Institute, NIH, Bethesda, Maryland; and 4Department of Radiation Genetics, Graduate School of Medicine, Kyoto University, Yoshidakonoe, Sakyo-ku, Kyoto, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yiping Zhang
1Developmental Therapeutics Branch, Laboratory of Molecular Pharmacology, Center for Cancer Research; 2National Clinical Target Validation Laboratory; 3Division of Cancer Treatment and Diagnosis, National Cancer Institute, NIH, Bethesda, Maryland; and 4Department of Radiation Genetics, Graduate School of Medicine, Kyoto University, Yoshidakonoe, Sakyo-ku, Kyoto, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jiuping Ji
1Developmental Therapeutics Branch, Laboratory of Molecular Pharmacology, Center for Cancer Research; 2National Clinical Target Validation Laboratory; 3Division of Cancer Treatment and Diagnosis, National Cancer Institute, NIH, Bethesda, Maryland; and 4Department of Radiation Genetics, Graduate School of Medicine, Kyoto University, Yoshidakonoe, Sakyo-ku, Kyoto, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Shunichi Takeda
1Developmental Therapeutics Branch, Laboratory of Molecular Pharmacology, Center for Cancer Research; 2National Clinical Target Validation Laboratory; 3Division of Cancer Treatment and Diagnosis, National Cancer Institute, NIH, Bethesda, Maryland; and 4Department of Radiation Genetics, Graduate School of Medicine, Kyoto University, Yoshidakonoe, Sakyo-ku, Kyoto, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Joel Morris
1Developmental Therapeutics Branch, Laboratory of Molecular Pharmacology, Center for Cancer Research; 2National Clinical Target Validation Laboratory; 3Division of Cancer Treatment and Diagnosis, National Cancer Institute, NIH, Bethesda, Maryland; and 4Department of Radiation Genetics, Graduate School of Medicine, Kyoto University, Yoshidakonoe, Sakyo-ku, Kyoto, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Beverly Teicher
1Developmental Therapeutics Branch, Laboratory of Molecular Pharmacology, Center for Cancer Research; 2National Clinical Target Validation Laboratory; 3Division of Cancer Treatment and Diagnosis, National Cancer Institute, NIH, Bethesda, Maryland; and 4Department of Radiation Genetics, Graduate School of Medicine, Kyoto University, Yoshidakonoe, Sakyo-ku, Kyoto, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
James H. Doroshow
1Developmental Therapeutics Branch, Laboratory of Molecular Pharmacology, Center for Cancer Research; 2National Clinical Target Validation Laboratory; 3Division of Cancer Treatment and Diagnosis, National Cancer Institute, NIH, Bethesda, Maryland; and 4Department of Radiation Genetics, Graduate School of Medicine, Kyoto University, Yoshidakonoe, Sakyo-ku, Kyoto, Japan
1Developmental Therapeutics Branch, Laboratory of Molecular Pharmacology, Center for Cancer Research; 2National Clinical Target Validation Laboratory; 3Division of Cancer Treatment and Diagnosis, National Cancer Institute, NIH, Bethesda, Maryland; and 4Department of Radiation Genetics, Graduate School of Medicine, Kyoto University, Yoshidakonoe, Sakyo-ku, Kyoto, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yves Pommier
1Developmental Therapeutics Branch, Laboratory of Molecular Pharmacology, Center for Cancer Research; 2National Clinical Target Validation Laboratory; 3Division of Cancer Treatment and Diagnosis, National Cancer Institute, NIH, Bethesda, Maryland; and 4Department of Radiation Genetics, Graduate School of Medicine, Kyoto University, Yoshidakonoe, Sakyo-ku, Kyoto, Japan
1Developmental Therapeutics Branch, Laboratory of Molecular Pharmacology, Center for Cancer Research; 2National Clinical Target Validation Laboratory; 3Division of Cancer Treatment and Diagnosis, National Cancer Institute, NIH, Bethesda, Maryland; and 4Department of Radiation Genetics, Graduate School of Medicine, Kyoto University, Yoshidakonoe, Sakyo-ku, Kyoto, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1158/1535-7163.MCT-13-0803 Published February 2014
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Article Figures & Data

Figures

  • Tables
  • Additional Files
  • Figure 1.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 1.

    Comparative PARP catalytic inhibition of BMN 673. A, chemical structures of BMN 673, olaparib (AZD2281), rucaparib (AG-014699), and NAD+. The nicotinamide moiety is outlined in dotted lines. Arrows in the BMN 673 structure indicate chiral centers involved in drug activity (see Supplementary Fig. S1). B, catalytic PARP inhibition potency of BMN 673 in comparison with olaparib and rucaparib. Total PAR levels in wild-type DT40 cells were examined by Western blotting against PAR 30 minutes after the indicated drug treatments. The asterisk represents a nonspecific band. C, PAR levels in drug-treated wild-type DT40 and DU145 cells measured by ELISA. Cells were incubated with the indicated concentrations of PARP inhibitors for 2 hours. PAR levels without drug treatment were set as 100% in each cell line.

  • Figure 2.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 2.

    BMN 673 is markedly more cytotoxic than olaparib and rucaparib while requiring PARP1/2 for activity. For all experiments, viability curves were derived after continuous treatment for 72 hours with the indicated PARP inhibitors in the indicated cell lines. Cellular ATP concentration was used to measure cell viability. The viability of untreated cells was set as 100%. Error bars represent SD (n ≥ 3). A, viability curves of wild-type, PARP1−/−, and BRCA2tr/− DT40 cells. Drug IC90 values are tabulated at the bottom. B, viability curves of DU145 (human prostate cancer) and EW8 (Ewing's sarcoma) cells. Drug IC90 values are tabulated at the bottom. C, viability curves of PARP1−/− DT40 cell line to high concentrations of the PARP inhibitors. D, viability curves of MDA-MB231 (human breast cancer) cells.

  • Figure 3.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 3.

    Comparison of the sensitivity patterns in the three PARP inhibitors across the NCI60 cell lines. The IC50 obtained from the NCI60 databases (refs. 35, 41; http://discover.nci.nih.gov/cellminer) is plotted for each cell line. Cell lines are colored according to tissue of origin (41). NA, data not available.

  • Figure 4.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 4.

    Comparative trapping of PARP1- and PARP2–DNA complexes by BMN 673, olaparib, and rucaparib. PARP–DNA complexes were determined by Western blot analyses of chromatin-bound fractions from drug-treated DT40 cells (A) and DU145 cells (B). DT40 and DU145 treatments were for 30 minutes and 4 hours, respectively. Blots were probed with the indicated antibodies. Histone H3 was used as positive markers for chromatin-bound fractions and as loading control. The blots of lanes 1 to 4 are identical to the blots of lanes 8 to 11 for PARP2 in B. The blots are representative of multiple experiments.

  • Figure 5.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 5.

    Biochemical trapping of PARP1 by BMN 673. A, scheme of the fluorescence anisotropy (FA) binding assay. The star indicates the site labeled on the DNA substrate with Alexa Fluor 488. Unbound nicked DNA substrate rotates fast and gives low fluorescence anisotropy. PARP1 binding to the substrate slows the rotation and gives high fluorescence anisotropy. Addition of NAD+ leads to PARP1 dissociation from DNA due to autoPARylation. B, concentration-dependent PARP1–DNA association in the presence of BMN 673 or olaparib. Fluorescence anisotropy was measured 40 minutes after adding NAD+. C, time-course of PARP1–DNA dissociation in the presence of BMN 673 and olaparib (0.12 μmol/L each). Addition of NAD+ in the absence of PARP inhibitor immediately reduces PARP1–DNA complexes (no drug, DMSO control). In the absence of NAD+, PARP1–DNA complexes remain stable for at least 180 minutes (no NAD+). Data are mean ± SEM (n = 3).

  • Figure 6.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 6.

    BMN 673 enhances the cytotoxicity of alkylating agents more efficiently than olaparib and rucaparib. A, survival curves of wild-type DT40 cells treated with MMS alone (upper curves labeled “0”) or with the indicated concentrations of PARP inhibitors (at the concentration shown beside each curve in micromolar units). The viability of untreated cells was set as 100%. Data are mean ± SD (n ≥ 3). B, PARP1−/− cells are hypersensitive to MMS (compare with upper curves in A) and resistant to the PARP inhibitors. C, viability curves of the indicated human cancer cells treated with MMS in combination with the indicated PARP inhibitors (the concentration of each PARP inhibitor is shown beside each curve). The viability of untreated cells was set as 100%. Data are mean ± SD (n ≥ 3). D, same as C but using temozolomide instead of MMS in prostate cancer DU145 cells.

Tables

  • Figures
  • Additional Files
  • Table 1.

    Summary of the IC50 and IC90 PAR level inhibitions for each drug in DT40 and DU145 cells

    IC50, nmol/LIC90, nmol/L
    DrugDT40DU145DT40DU145
    BMN 6734113071
    Olaparib61880120
    Rucaparib2118100120
  • Table 2.

    Pearson correlation coefficient analyses of Fig. 3 between the drugs

    BMN 673OlaparibRucaparib
    BMN 6731.00
    Olaparib0.521.00
    Rucaparib0.040.161.00

    NOTE: Numbers in italic indicate highly significant correlations (P < 0.001).

    Additional Files

    • Figures
    • Tables
    • Supplementary Data

      Files in this Data Supplement:

      • Supplementary Figures 1 - 4 - PDF file - 1641K, Supplementary figure 1. Stereospecific targeting of PARP by BMN 673. Supplementary figure 2. Lack of effect of PARP inhibition on ATP concentration. Supplementary figure 3. Flow cytometry analyses after treatment with different PARP inhibitors. Supplementary figure 4. Stereospecific poisoning of PARP by BMN 673.
    PreviousNext
    Back to top
    Molecular Cancer Therapeutics: 13 (2)
    February 2014
    Volume 13, Issue 2
    • Table of Contents
    • Table of Contents (PDF)
    • About the Cover

    Sign up for alerts

    View this article with LENS

    Open full page PDF
    Article Alerts
    Sign In to Email Alerts with your Email Address
    Email Article

    Thank you for sharing this Molecular Cancer Therapeutics article.

    NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

    Enter multiple addresses on separate lines or separate them with commas.
    Stereospecific PARP Trapping by BMN 673 and Comparison with Olaparib and Rucaparib
    (Your Name) has forwarded a page to you from Molecular Cancer Therapeutics
    (Your Name) thought you would be interested in this article in Molecular Cancer Therapeutics.
    CAPTCHA
    This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
    Citation Tools
    Stereospecific PARP Trapping by BMN 673 and Comparison with Olaparib and Rucaparib
    Junko Murai, Shar-Yin N. Huang, Amèlie Renaud, Yiping Zhang, Jiuping Ji, Shunichi Takeda, Joel Morris, Beverly Teicher, James H. Doroshow and Yves Pommier
    Mol Cancer Ther February 1 2014 (13) (2) 433-443; DOI: 10.1158/1535-7163.MCT-13-0803

    Citation Manager Formats

    • BibTeX
    • Bookends
    • EasyBib
    • EndNote (tagged)
    • EndNote 8 (xml)
    • Medlars
    • Mendeley
    • Papers
    • RefWorks Tagged
    • Ref Manager
    • RIS
    • Zotero
    Share
    Stereospecific PARP Trapping by BMN 673 and Comparison with Olaparib and Rucaparib
    Junko Murai, Shar-Yin N. Huang, Amèlie Renaud, Yiping Zhang, Jiuping Ji, Shunichi Takeda, Joel Morris, Beverly Teicher, James H. Doroshow and Yves Pommier
    Mol Cancer Ther February 1 2014 (13) (2) 433-443; DOI: 10.1158/1535-7163.MCT-13-0803
    del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
    • Tweet Widget
    • Facebook Like
    • Google Plus One

    Jump to section

    • Article
      • Abstract
      • Introduction
      • Materials and Methods
      • Results
      • Discussion
      • Disclosure of Potential Conflicts of Interest
      • Authors' Contributions
      • Grant Support
      • Acknowledgments
      • Footnotes
      • References
    • Figures & Data
    • Info & Metrics
    • PDF
    Advertisement

    Related Articles

    Cited By...

    More in this TOC Section

    • IGF2 Overexpression Predicts IGF1R/INSR Inhibitor Response
    • OPCML Sensitizes HER2+ Cancers to Anti-HER2/EGFR Therapy
    • Ormeloxifene and Prostate Cancer
    Show more Cancer Biology and Signal Transduction
    • Home
    • Alerts
    • Feedback
    • Privacy Policy
    Facebook  Twitter  LinkedIn  YouTube  RSS

    Articles

    • Online First
    • Current Issue
    • Past Issues
    • Meeting Abstracts

    Info for

    • Authors
    • Subscribers
    • Advertisers
    • Librarians

    About MCT

    • About the Journal
    • Editorial Board
    • Permissions
    • Submit a Manuscript
    AACR logo

    Copyright © 2021 by the American Association for Cancer Research.

    Molecular Cancer Therapeutics
    eISSN: 1538-8514
    ISSN: 1535-7163

    Advertisement